<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="iso-abbrev">Med Oral Patol Oral Cir Bucal</journal-id><journal-id journal-id-type="publisher-id">Medicina Oral S.L.</journal-id><journal-title-group><journal-title>Medicina Oral, Patolog&#x000ed;a Oral y Cirug&#x000ed;a Bucal</journal-title></journal-title-group><issn pub-type="ppub">1698-4447</issn><issn pub-type="epub">1698-6946</issn><publisher><publisher-name>Medicina Oral S.L.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39864078</article-id><article-id pub-id-type="pmc">PMC11972647</article-id>
<article-id pub-id-type="publisher-id">26706</article-id><article-id pub-id-type="doi">10.4317/medoral.26706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject><subj-group><subject>Medically compromised patients in Dentistry</subject></subj-group></subj-group></article-categories><title-group><article-title>Does oral hygiene prevents nosocomial infections in hospitalized patients? A systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miyahira</surname><given-names>Karla Magnan</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Martins</surname><given-names>Mariana Leonel</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liberato</surname><given-names>Walleska Freij&#x000f3;</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Magno</surname><given-names>Marcela Bara&#x000fa;na</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Dennis de Carvalho</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ten&#x000f3;rio</surname><given-names>Jefferson R</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Maia</surname><given-names>Lucianne Cople</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Castro</surname><given-names>Gl&#x000f3;ria Fernanda Barbosa de Ara&#x000fa;jo</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pediatric Dentistry and Orthodontics, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil</aff><aff id="A2"><label>2</label>Department of Dentistry, School of Dentistry, Universidade Federal Fluminense, Rio de Janeiro, RJ, Brazil</aff><aff id="A3"><label>3</label>Department of Dentistry, School of Dentistry, Universidade Est&#x000e1;cio de S&#x000e1;, Rio de Janeiro, RJ, Brazil</aff><aff id="A4"><label>4</label>Department of Pathology and Oral Diagnosis, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil</aff><author-notes><corresp> Prof&#x000ba; Rodolpho Paulo Rocco 325
Cidade Universit&#x000e1;ria da Universidade Federal do Rio de Janeiro
Zipcode: 21941-913. Rio de Janeiro, RJ, Brazil
, E-mail: <email>gfbacastro@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>26</day><month>1</month><year>2025</year></pub-date><volume>30</volume><issue>2</issue><fpage>e179</fpage><lpage>e191</lpage><history><date date-type="accepted"><day>7</day><month>1</month><year>2025</year></date><date date-type="received"><day>10</day><month>5</month><year>2024</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2025 Medicina Oral S.L.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/2.5/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background </title><p> This study aimed to evaluate the impact of oral hygiene (OH) with chlorhexidine (CHX) on the evolution of nosocomial infections (NI).</p></sec><sec><title>Material and Methods </title><p> Electronic searches were carried out in PubMed, Scopus, Cochrane Library, Web of Science, VHL, and Grey Literature databases. Randomized clinical trials were included. Methodological quality and risk of bias were assessed using RoB 2.0. Meta-analyses were carried out comparing patients who did or did not receive OH with CHX (0.05%, 0.12% and 2%) for NI, Ventilator-Associated Pneumonia (VAP), S. aureus infection (SA), duration of mechanical ventilation (MV), length of hospital stay and Intensive Care Unit (ICU). The certainty of evidence (CE) was evaluated with GRADE approach.</p></sec><sec><title>Results </title><p> Thirteen studies were selected for quantitative and qualitative synthesis. The risk for VAP (RR 0.72 [0.58, 0.90], <italic>p</italic>=0.003) and NI (RR 0.70 [0.58, 0.83], <italic>p</italic>&#x0003c;0.001) were lower in patients of the CHX groups compared to controls, independently for [CHX] used for NI (RR&#x02265;0.49, p&#x02264;0.03). Patients who received CHX 2&#x000d7;/day presented similar risk to control (RR 0.98 [0.75, 1.30], <italic>p</italic>=0.91); while 3 and 4&#x000d7;/day or more (RR&#x02265;0.52, p&#x02264;0.002) presented lower risk for NI. Similar risk for SA was observed among groups (RR 0.42 [0.14, 1.26], <italic>p</italic>=0.12). The average days of hospitalization (<italic>p</italic>=0.67), ICU stay (<italic>p</italic>=0.37) and MV (<italic>p</italic>=0.57) did not differ between the groups. CE ranged from very low to moderate.</p></sec><sec><title>Conclusions </title><p> OH with CHX reduced NI, regardless of concentration, when used 3&#x000d7;/day or more. However, it had no effect against AS and did not reduce length of hospital stay.</p><p><bold> Key words:</bold>Nosocomial infections, dental plaque, intensive care patients, oral decontamination, chlorhexidine.</p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p>Hospitalized patients, especially those admitted to intensive care units (ICU), are debilitated and dependent on self-care, thus requiring comprehensive care through a multidisciplinary team (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B4" ref-type="bibr">4</xref>). Oral hygiene is extremely important for both oral and general health and can be performed in a hospital by medical, nursing, and dental staff (<xref rid="B5" ref-type="bibr">5</xref>). The oropharynx serves as the main reservoir of bacterial colonization in the upper airways, and colonization by aerobic pathogens occurs rapidly in ICU patients due to epithelial injuries, mucosal dryness, reduced salivary secretion, changes in local antibacterial resistance, among other factors (<xref rid="B6" ref-type="bibr">6</xref>). After 48 hours of ICU admission, the oral microbiota of critically ill patients undergoes significant changes, with the presence of more virulent and resistant microorganisms becoming frequent (<xref rid="B7" ref-type="bibr">7</xref>).</p><p>In this context, dental biofilm can provide a habitat for these microorganisms and the bacteria from the oropharynx can be aspirated and can trigger nosocomial infections (NI) (<xref rid="B8" ref-type="bibr">8</xref>). These infections have been associated with higher ICU mortality rates, increased length of stay and the financial burden on the health system (<xref rid="B9" ref-type="bibr">9</xref>). It is noteworthy that the most frequent NI among ICU patients is ventilator-associated pneumonia (VAP), with a prevalence of 5% to 9.6% and a mortality rate of 23.6%-47.5% throughout the world (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The relationship between oral bacteria and nosocomial infections justifies the implementation of strategies capable of controlling the amount of biofilm present in the oral cavity and the decontamination of the oropharynx (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B11" ref-type="bibr">11</xref>). Previous studies suggest the topical use of chlorhexidine (CHX) in the oral cavity as a standard protocol for reducing VAP due to its efficacy against a wide range of microorganism (<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). Despite knowledge of the antibacterial action of CHX, there is no consensus in the literature on the best frequency of use and concentration of this antimicrobial (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Although it is an important topic in oral medicine, there is a difficulty on the part of health professionals in implementing oral hygiene protocols or guidelines for the prevention of NI due to limited knowledge and lack of consensus among existing protocols. Therefore, the aim of this systematic review and meta-analysis was to assess the impact of oral hygiene with CHX on the evolution of NI.</p></sec><sec><title>Material and Methods</title><p>To carry out this systematic review and meta-analysis, the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (http://www.prisma-statement.org) were followed, being registered in the database PROSPERO under the protocol CRD42019134699. The following question was developed according to the acronym PICO: (P) hospitalized patient, (I) chlorhexidine, (C) placebo or toothbrushing, and (O) prevent nosocomial infection.</p><p>- Literature Search Strategy</p><p>Two examiners (KMM and MLM), guided by a librarian, performed the search process independently, without restriction of language and year, adapted to each database. The following electronic databases being searched: Scopus, Pubmed, Cochrane Library, Web of Science, BBO/Lilacs and the Grey Literature (OpenGrey and Google Scholar). MeSH terms, free terms and Boolean operators (OR, AND) are being used, organized according to the PICO search strategy described (<xref rid="T1" ref-type="table">Table 1</xref>). E-mail alerts were created in the databases to indicate new searches, being included articles until May 2023. Duplicate articles were identified and removed, being considered as only one.</p><p>- Eligibility Criteria</p><p>Randomized clinical trials (RCTs) were included which presented a group treated with CHX and a control group (treated with placebo or toothbrushing) in hospitalized patients for the assessment and control of dental biofilm. In vitro, in situ and animal studies were excluded, as well as case reports, literature reviews, observational studies or others that did not meet the inclusion criteria.</p><p>- Study Selection Process</p><p>Articles identified in databases and by manual search were compiled into a bibliographic reference manager (Online version of EndNote, Version X7; Thomson Reuters, Philadelphia, PA). After automatic and manual duplicated references removal, two review authors (K.M.M. and M.L.M.) performed the study selection, independently, through the evaluation of the titles and abstracts of all studies according to the eligibility criteria. Besides, when any title and abstract did not provide enough information for a definitive decision, the full text was retrieved and examined. Subsequently, all selected articles were read in full to confirm the eligibility. Any disagreements regarding the eligibility of studies for inclusion were resolved through consensus or with the help of a third author (G.F.B.A.C).</p><p>- Data Extraction </p><p>Two examiners (K.M.M. and M.L.M.) performed the complete reading and extraction of the data independently. A spreadsheet was created to standardize the data to be extracted, containing the following information: author, year, study design, sample size, source of sample, age of participants, sampling method, form of application, presentation form, responsible professional, CHX concentration, frequency of intervention, duration of interventions, mean of days hospitalized, type of infection and conclusion).</p><p>- Evaluation of Methodological Quality </p><p>The KMM and MLM examiners independently carried out the quality assessment. Methodological quality and risk of bias were assessed using the &#x0201c;Risk of Bias 2.0&#x02033; (RoB 2.0). For each item, scores representing low, uncertain or high risk of bias (RoB 2.0) were used.</p><p>Sequence generation; allocation concealment; and blinding of participants, personnel, and outcome assessors were defined as key criteria for classifying the methodological quality of the randomized studies. Disagreements between the review authors over the risk of bias were resolved by discussion, with involvement of a third review author (L.C.M.) when necessary.</p><p>- Meta-analysis</p><p>The studies data were analyzed using RevMan software (Review Manager v. 5.4.1, The Cochrane Collaboration; Copenhagen, Denmark) to evaluate the NI and related parameters in meta-analysis (MAs).</p><p>A quantitative analysis was carried out comparing patients who received (intervention) or did not receive (control) oral hygiene with CHX during hospitalization:</p><p>Nosocomial infection, VAP, S. aureus infection: the number of patients with infection (events) and the total number of patients who did and did not receive oral hygiene with CHX were used to calculate the risk ratio (RR) and 95% confidence interval (CI).</p><p>The analyses were carried out without and with a subgroup considering previous antibiotics (yes, no or unspecified), previous infection (yes, no or unspecified), CHX concentration (0.05%, 0.12% and 2%) and hygiene protocol (2&#x000d7;/day, 3&#x000d7;/day and 4&#x000d7;/day or more).</p><p>Length of hospitalization, length of ICU stay and length of mechanical ventilation. Analysis: mean, standard deviation and the number of patients assessed in each group (whether or not they received oral hygiene with CHX) were extracted from the studies and the mean difference (MD) and 95% CI were calculated, since the included studies used similar methods and unit ranges.</p><p>Random effects were applied and heterogeneity was tested using the I2 index. A funnel plot was generated for analysis that included ten or more studies and the <italic>p-value</italic> of publication bias was calculated using the JAMOVI software.</p><p>- Certainty of Evidence</p><p>The certainty of the evidence (certainty in the estimates of effect) was determined for each outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<xref rid="B16" ref-type="bibr">16</xref>). With the GRADE approach, RCTs start as high quality evidence, however, the quality or certainty of the evidence decreases to moderate, low or very low if there are serious or very serious problems related to risk of bias, imprecision, inconsistency, indirectness and publication bias.</p></sec><sec><title>Results</title><p>Initially, 1073 articles were identified. After removing duplicates, 649 studies remained. Of these, 599 were excluded after reading the titles and abstracts, and 50 were selected for reading the text in full. After careful reading of the full text, 37 articles were excluded because they did not meet the eligibility criteria, and 13 articles were selected and included in the quantitative and qualitative synthesis (Fig. <xref rid="F1" ref-type="fig">1</xref>) (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>). The characteristics of the studies are described and summarized individually in <xref rid="T2" ref-type="table">Table 2</xref>.</p><p>The risk of bias in the included studies is shown in Supplement 1. Five studies (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B25" ref-type="bibr">25</xref>), had &#x0201c;uncertain risk of bias&#x0201d; only in the &#x0201c;other potential threats to validity&#x0201d; and had &#x0201c;low risk of bias&#x0201d; in all other domains; therefore, these studies were the gold standard articles included in this systematic review. One study (<xref rid="B21" ref-type="bibr">21</xref>) presented &#x0201c;uncertain risk of bias" in the domains &#x0201c;selective outcome reporting&#x0201d; and &#x0201c;other potential threats to validity&#x0201d;.</p><p>
<fig position="float" id="F1"><label>Figure 1</label><caption><p>PRISMA flowchart of search results in databases.</p></caption><graphic xlink:href="medoral-30-e179-g001" position="float"/></fig>
</p><p>Other study (<xref rid="B22" ref-type="bibr">22</xref>) presented an &#x0201c;uncertain risk of bias&#x0201d; for the domains &#x0201c;sequence generation&#x0201d;, &#x0201c;allocation concealment&#x0201d;, &#x0201c;blinding of participants, personnel and outcome assessors&#x0201d;. Six studies (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>) were considered as "high risk of bias" in one or more of the following domains: "sequence generation", "allocation concealment" and &#x0201c;other potential threats to validity&#x0201d;.</p><p>Thirteen studies were included in analyses of NI. In total, 4.121 patients were evaluated and the risk for NI were lower in patients who received oral hygiene with CHX compared to controls (RR 0.70 [0.58, 0.83], I2=35%, <italic>p</italic>&#x0003c;0.001) (Fig. <xref rid="F2" ref-type="fig">2</xref>) (Supplement 2), with moderate certainty of evidence (<xref rid="T3" ref-type="table">Table 3</xref>) and no publication bias (Supplement 1). Similar result was observed for VAP (RR 0.72 [0.58, 0.90], I2=32%, <italic>p</italic>=0.003) (Fig. <xref rid="F3" ref-type="fig">3</xref>) without publication bias (Supplement 3). However, for NI not PAV patients who received oral hygiene with CHX presented similar risk than those that received oral hygiene without CHX (RR 0.72 [0.52, 1.00], I2=50%, <italic>p</italic>=0.05) (Supplement 4), with low certainty of evidence (<xref rid="T3" ref-type="table">Table 3</xref>).</p><p>NI - subgroup analysis. Thirteen studies were included in these analyses and <xref rid="T4" ref-type="table">Table 4</xref> show subgroup results.</p><p>For antibiotic prophylaxis, patients who received oral hygiene with CHX had a lower risk of NI than controls, when studies that included patients with (RR 0.74 [0.59, 0.94] I2= 3% <italic>p</italic>=0.01) and without (RR 0.53 [0.32, 0.87], I2= 45%, <italic>p</italic>=0.01) antibiotic prophylaxis were analyzed as subgroups.</p><p>Patients who received oral hygiene with CHX had a lower risk for NI than controls, for subgroup of studies that did not include patients with previous infection (RR 0.62 [0.41, 0.93], I2= 29%, <italic>p</italic>=0.02). However, for the subgroup of studies that included patients with previous infection, patients who received oral hygiene with CHX had a similar risk of NI than controls (RR 0.80 [0.63, 1.03], I2= 0%, <italic>p</italic>=0.09).</p><p>Patients who received oral hygiene in any concentration (CHX 0.05%, 0.12% and 0.2%) had a lower risk of NI than controls (RR 0.61 [0.39, 0.95], <italic>p</italic>=0.03; RR 0.80 [0.66, 0.96], I2=31%, <italic>p</italic>=0.02; and RR 0.49 [0.35, 0.68], <italic>p</italic>&#x0003c;0.0001, respectively).&#x000a0;</p><p>A similar risk to controls was observed for patients who received oral hygiene with CHX twice a day (RR 0.98 [0.75, 1.30], <italic>p</italic>=0.91); while patients who received oral hygiene with CHX three times a day (RR 0.52 [0.34, 0.78], <italic>p</italic>=0.002) and four times a day or more (RR 0.67 [0.57, 0.78], <italic>p</italic>&#x0003c;0.0001) had a lower risk for NI than controls.</p><p>S. aureus infection. Five studies were included in this analysis. Patients who received oral hygiene with CHX and controls presented similar risk of nosocomial infection (RR 0.42 [0.14, 1.26], I2=0%, <italic>p</italic>=0.12) (Supplement 5). The certainty of evidence is low (Table III).</p><p>- Length of stay in the hospital, length of stay in the ICU, duration of mechanical ventilation.</p><p>Mean of days hospitalized (MD -1.03 [-5.79, 3.72], I2=62%, <italic>p</italic>=0.67) (Supplement 6), admitted to ICU (MD -0.51 [-1.63, 0.61], I2=75%, <italic>p</italic> =0.37) (Fig. <xref rid="F4" ref-type="fig">4</xref>) are similar to patients who received oral hygiene with CHX compared to controls. The certainty of the evidence is very low (<xref rid="T3" ref-type="table">Table 3</xref>).</p><p>
<fig position="float" id="F2"><label>Figure 2</label><caption><p>Risk for nosocomial infection.</p></caption><graphic xlink:href="medoral-30-e179-g002" position="float"/></fig>
</p><p>
<fig position="float" id="F3"><label>Figure 3</label><caption><p>Risk for VAP infection.</p></caption><graphic xlink:href="medoral-30-e179-g003" position="float"/></fig>
</p><p>
<fig position="float" id="F4"><label>Figure 4</label><caption><p>Mean difference of days admitted in ICU. </p></caption><graphic xlink:href="medoral-30-e179-g004" position="float"/></fig>
</p><p>Two funnel plots were created to analyze the effect of the CHX and control groups (one for VAP risk and the other for NI risk). No publication bias was detected in both analyzes (<italic>p</italic>=0,05 and <italic>p</italic>=0,05, respectively) (Supplement 2, Supplement 3).</p></sec><sec><title>Discussion</title><p>This systematic review selected and evaluated 13 scientific clinical studies that analyzed the effect of chlorhexidine in preventing nosocomial infections (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B24" ref-type="bibr">24</xref>). It is known that chlorhexidine is a broad-spectrum chemical antiseptic, capable of acting both on gram positive and gram negative bacteria. Its mechanism of action promotes damage to the cell walls of bacteria and modifies the osmotic balance of microorganisms (<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>). One study showed that 70% of ICUs in North America and Europe implement chlorhexidine in daily oral care of patients for the prevention of VAP (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>However, the oral hygiene protocols recommended worldwide in hospitals differ with regard to the form of presentation, frequency of application and concentration of chlorhexidine due to the lack of scientific evidence to support the use of a universal protocol.</p><p>In this context, it was possible to identify that most of the selected studies used chlorhexidine in solution form (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B24" ref-type="bibr">24</xref>) but three studies opted for chlorhexidine gel (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B25" ref-type="bibr">25</xref>). Even though it is not the most widely used, chlorhexidine gel may have been chosen because of its high viscosity, which contributes to its long duration of action and greater adherence to tooth surfaces (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>According to the risk of bias assessment, two of the three articles that advocated the use of chlorhexidine gel were classified as having a low risk of bias, while (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B25" ref-type="bibr">25</xref>) were classified as having an uncertain risk of bias. Meanwhile, one study (<xref rid="B18" ref-type="bibr">18</xref>) presented placebos that were similar in terms of texture, taste and smell, which allowed for greater blinding of the studies. In one study (<xref rid="B21" ref-type="bibr">21</xref>), the placebo was not similar, as the authors reported that it was not possible to obtain an identical gel. However, they make it clear that this did not interfere with the research, since the entire team was blinded.</p><p>The other studies that used chlorhexidine solution, (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>) were classified as having low risk of bias in all domains, except for the secondary domain (Other potential threats to validity), which was classified as having uncertain risk. These studies had a placebo with similar characteristics to the intervention group, contributing to better blinding.</p><p>One of the studies (<xref rid="B22" ref-type="bibr">22</xref>) that used the solution form did not specify the type of placebo that was compared to chlorhexidine and three other studies compared chlorhexidine with brushing, making it difficult to blind the participants (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Two studies (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B17" ref-type="bibr">17</xref>) presented an uncertain risk of bias in terms of blinding the participants. However, in one study (<xref rid="B3" ref-type="bibr">3</xref>) it was not possible to use a placebo, as the chlorhexidine de-adoption analyses were carried out at different times.</p><p>After two months of constant use of chlorhexidine in the patient's oral hygiene, this use was discontinued and only one oral care package was implemented (oral assessment and tooth brushing twice a day, mouth moisturizing, lip moisturizing with additional secretion removal every 4 hours) for another two months.</p><p>Two research groups aimed to compare chlorhexidine with brushing, but the authors did not report blinding (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B17" ref-type="bibr">17</xref>). However, Alja'afreh <italic>et al</italic>. (2019) justified that the outcome did not change due to the lack of blinding (<xref rid="B2" ref-type="bibr">2</xref>). However, it should be known that brushing, in addition to making blinding difficult, can be seen as a source of vision, as it is a mechanical method capable of promoting the reduction and disorganization of the biofilm and, in this way, interfering with the results of the study conducted by Munro <italic>et al</italic>. (2009) (<xref rid="B17" ref-type="bibr">17</xref>). Thus, two studies (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B23" ref-type="bibr">23</xref>) also showed a low risk of bias regarding the blinding of the participants, while Azimi <italic>et al</italic>. (2016) (<xref rid="B24" ref-type="bibr">24</xref>) reported that the evaluators were blind but did not detail how this blinding was done, being classified as having an uncertain risk of bias.</p><p>Regarding the frequency of chlorhexidine application, it ranged from 2 to 6&#x000d7;/day, with only 3 studies using 2&#x000d7;/day application, as seen in three studies (<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B25" ref-type="bibr">25</xref>). The other studies recommended frequencies of 3, 4 and 6&#x000d7;/day (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B21" ref-type="bibr">21</xref>-<xref rid="B24" ref-type="bibr">24</xref>). According to a meta-analysis carried out in the present review, the studies that recommended the use of chlorhexidine twice a day revealed a similar risk for the development of nosocomial infections in both groups. But studies that used chlorhexidine 3 times or more revealed a lower risk for this type of infection in the intervention group. This may indicate that higher frequencies of daily use are more effective.</p><p>The concentration of chlorhexidine used varied between 0.05%, 0.12% and 0.2%. A meta-analysis showed that patients who received chlorhexidine, regardless of the concentration used, had a lower risk of nosocomial infection, as seen in most of the studies analyzed (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>). The study by Alja'afreh <italic>et al</italic>. (2019) (<xref rid="B2" ref-type="bibr">2</xref>) was the only one that recommended a concentration of 0.05%. Although it is a lower concentration, it presented superior results in relation to the incidence of VAP. One fact that can be explained by the choice of a lower concentration in this study is the concern with possible side effects of chlorhexidine. Despite being considered the gold standard, chlorhexidine, especially at high concentrations such as 2%, can cause oral lesions, break the integrity of the oral mucosa and contribute to the development of infections (<xref rid="B27" ref-type="bibr">27</xref>). Given this divergence in the literature, note that lower concentrations are as effective as higher concentrations for the prevention of VAP and that greater benefit and lower risk should be considered. However, further research must be carried out so that a safer and more effective concentration can be defined.</p><p>Chlorhexidine oral rinse has been shown to be effective in preventing nosocomial respiratory tract infection in heart disease patients (<xref rid="B20" ref-type="bibr">20</xref>). Thus, when we evaluated the effectiveness of 0.12% chlorhexidine, it proved to be more effective in the oral hygiene of these patients than in patients admitted to the ICU (<xref rid="B20" ref-type="bibr">20</xref>). However, this transparency can be justified by the intubation process. Endotracheal tubes are often inserted in ICU patients on an emergency basis, without any preparation or cleaning. Unlike patients undergoing cardiac surgery, who undergo this step electively, with prior cleaning of the oral cavity (<xref rid="B20" ref-type="bibr">20</xref>). In this sense, J&#x000e1;como <italic>et al</italic>. (2011) (<xref rid="B20" ref-type="bibr">20</xref>) e Cabov <italic>et al</italic>. (2010) (<xref rid="B21" ref-type="bibr">21</xref>) aimed to evaluate the effect of oral chlorhexidine in patients undergoing cardiac surgery. However, Cabov <italic>et al</italic>. (2010) (<xref rid="B21" ref-type="bibr">21</xref>) demonstrated that chlorhexidine 0.12 does not impair the incidence of nosocomial pneumonia and VAP in children undergoing cardiac surgery. Unlike the study by J&#x000e1;como <italic>et al</italic>. (2011) (<xref rid="B20" ref-type="bibr">20</xref>), which showed positive results in relation to the use of 0.12% chlorhexidine.</p><p>The application method was also applied and varied between swab, application with gloved hands, brushing and mouthwash. Some authors reported the time of application of chlorhexidine, which ranged from 30 seconds to 6 minutes. Note that the techniques used were different, as well as the results obtained. The Associa&#x000e7;&#x000e3;o de Medicina Intensiva Brasileira (AMIB) developed a standard procedure for carrying out oral hygiene for patients admitted to the ICU. According to the AMIB protocol, it should be performed twice a day, with a 0.12% chlorhexidine solution and with the help of a consistency with gaze. The AMIB does not cite the time required to carry out the standard procedure but recommends a step-by-step procedure that is divided into extraoral and intraoral care. This protocol recommends that intraoral movements be performed in the posteroanterior direction, that they be gentle so as not to injure the soft tissues and that they be performed on all structures of the oral cavity (buccal mucosa; inner part of the lips; gingiva; palate; dorsum of the tongue; teeth; fixed prostheses and orotracheal tube). Although there is no universal recommendation to date, it is possible to suggest that it doesn't matter the method of application or the time associated with it, but rather the manner and care with which hygiene is carried out.</p><p>Although oral hygiene is extremely important, monitoring the hospital environment is not a simple task. Hospitalization in Intensive Care requires care from a qualified multidisciplinary team. And for many patients, only the dentist can provide the level of attention and care needed (<xref rid="B23" ref-type="bibr">23</xref>). In addition, it is necessary to verify the dental needs to reduce the oral microbial load and establish the oral health of the patient. This corroborates the study by Bellissimo-Rodrigues <italic>et al</italic>. (2009) (<xref rid="B23" ref-type="bibr">23</xref>) which showed that patients treated by dentists had a better rate of oral hygiene than patients treated exclusively by nursing staff during their ICU stay.</p><p>Dale <italic>et al</italic>. (2021) (<xref rid="B3" ref-type="bibr">3</xref>) also reported on the nursing team's difficulties in accessing the oral cavity and practicing oral hygiene for adult patients under mechanical ventilation. However, all the studies included in this review had the nurse as the professional responsible for oral hygiene. Only one study mentioned the role of the dental surgeon in guiding the protocol used (<xref rid="B22" ref-type="bibr">22</xref>), even though it is the dentist's role to supervise and properly guide the nurses or nursing technicians to carry out satisfactory and effective oral hygiene (<xref rid="B26" ref-type="bibr">26</xref>). This can be interpreted as a source of bias, since only a few articles reported that the nursing team had been trained before the research began (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B25" ref-type="bibr">25</xref>) and, of those that did, only 4 described how this training was carried out.</p><p>The previous use of antibiotics was also considered a source of bias, as these antimicrobials can potentiate and interfere with the preventive effect of the protocols adopted (<xref rid="B28" ref-type="bibr">28</xref>-<xref rid="B30" ref-type="bibr">30</xref>). On the other hand, the unnecessary and excessive consumption of antibiotics allows for the selection of resistant strains, contributing to a reduction in the effect of these drugs (<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B30" ref-type="bibr">30</xref>).</p><p>However, we know that the hospital environment is a place where there is a high risk of contamination and, due to the patients' impairment, the administration of these antimicrobials is a preventative strategy and is often necessary, as is the case with patients undergoing heart surgery. Therefore, the selection of antibiotic-free patients would limit the studies to be included for this review.</p><p>It is recognized that the microorganisms most commonly associated with hospital-acquired pneumonia are Acinetobacter spp, P. aeruginosa, <italic>E. coli</italic>, Klebsiella pneumonia (K. pneumoniae), and S. aureus (especially MRSA). According to the meta-analysis carried out, both the patients who received chlorhexidine and the control group had a similar risk of S. Aureus infection. It is worth noting that only five articles (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>) were included in this evaluation.</p><p>As for the participants, only 3 studies were prolonged in the pediatric ICU (<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B25" ref-type="bibr">25</xref>). It should be noted that most research is carried out in adults and that new studies need to be performed in children in order to have a greater source of data. Moreover, due to differences in age, immune system and microbiota, the data cannot be extrapolated to this population. It should be noted that VAP is the most common infection in pediatric ICUs, with a frequency ranging from 3% to 50% and a high incidence of mortality (<xref rid="B3" ref-type="bibr">3</xref>). Therefore, the prevention of VAP and the analysis of outcomes in this age group are extremely important for improving the care and quality of life of pediatric patients.</p><p>Although meta-analyses have not identified significant differences in terms of length of hospital stay between the control and intervention groups, the literature demonstrates that nosocomial infections result in increased length of stay. In this sense, concluded that patients with VAP have a longer stay in the ICU, with an average of 7 to 9 additional days, and consequently, a higher cost for the public and private system.</p><p>Despite the findings of this review, limitations include the scarcity of publications on the oral hygiene of hospitalized patients, the lack of information needed for data extraction in the selected articles, the low number of studies involving the pediatric ICU, the divergence in existing protocols, methodological limitations in primary studies in relation to blinding, and the impossibility of carrying out meta-analyses on the method of applying chlorhexidine and the time used due to the variability between studies.</p><p>Thus, it is suggested that new studies be developed to ease differences in protocols, facilitate analysis, development and implementation of a universal protocol. And from that, determine the safest and most effective chlorhexidine concentration. It is also important to have professionals trained and qualified to correctly carry out the oral hygiene of hospitalized patients, as well as the implementation of policies that encourage and supervise these practices in all hospitals and that defend the performance of the dental surgeon in the multidisciplinary team within the ICUs.</p></sec><sec><title>Conclusions</title><p>Chlorhexidine reduced nosocomial infections, regardless of concentration, when used 3x/day or more. However, it had no effect against S. aureus and did not reduce length of stay or mechanical ventilation time.</p></sec></body><back><ack><title>Acknowledgement</title><p>Declared none.</p></ack><sec><title>Funding</title><p>This study was supported by the Research Support Foundation of the State of Rio de Janeiro - FAPERJ.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><notes><title>Institutional Review Board Statement</title><p>Not applicable as this is a systematic review research.</p></notes><notes><title>Author Contributions</title><p>Conceptualization: Karla Magnan Miyahira; Gl&#x000f3;ria Fernanda Barbosa de Ara&#x000fa;jo Castro;
Methodology: Lucianne Cople Maia, Karla Magnan Miyahira, Mariana Leonel Martins;
Formal analysis and investigation: Marcela Bara&#x000fa;na Magno, Karla Magnan Miyahira; Walleska Freij&#x000f3; Liberato;
Writing - original draft preparation: Karla Magnan Miyahira, Dennis de Carvalho Ferreira;
Writing - review and editing: Jefferson R. Ten&#x000f3;rio, Lucianne Cople Maia, Gl&#x000f3;ria Fernanda Barbosa de Ara&#x000fa;jo Castro;
Supervision: Lucianne Cople Maia, Gl&#x000f3;ria Fernanda Barbosa de Ara&#x000fa;jo Castro.</p></notes><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Chawan</surname><given-names>NS</given-names></name><name><surname>Hazra</surname><given-names>A</given-names></name></person-group><article-title>Nosocomial infections in the intensive care unit: Incidence, risk factors, outcome and associated pathogens in a public tertiary teaching hospital of Eastern India</article-title><source>Indian J Crit Care Med</source><year>2015</year><volume>19</volume><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">25624645</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alja'afreh</surname><given-names>MA</given-names></name><name><surname>Mosleh</surname><given-names>SM</given-names></name><name><surname>Habashneh</surname><given-names>SS</given-names></name></person-group><article-title>The Effects of Oral Care Protocol on the Incidence of Ventilation-Associated Pneumonia in Selected Intensive Care Units in Jordan</article-title><source>Dimens Crit Care Nurs</source><year>2019</year><volume>38</volume><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">30499786</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>CM</given-names></name><name><surname>Rose</surname><given-names>L</given-names></name><name><surname>Carbone</surname><given-names>S</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>OM</given-names></name><name><surname>Burry</surname><given-names>L</given-names></name></person-group><article-title>Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial</article-title><source>Intensive Care Med</source><year>2021</year><volume>47</volume><fpage>1295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">34609548</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>ILA</given-names></name><name><surname>Bellissimo-Rodrigues</surname><given-names>WT</given-names></name><name><surname>Mussolin</surname><given-names>MG</given-names></name><name><surname>Innocentini</surname><given-names>LMAR</given-names></name><name><surname>Marangoni</surname><given-names>ATD</given-names></name><name><surname>Macedo</surname><given-names>LD</given-names></name></person-group><article-title>Impact of a dental care intervention on the hospital mortality of critically ill patients admitted to intensive care units: A quasi-experimental study</article-title><source>Am J Infect Control</source><year>2022</year><volume>50</volume><fpage>1156</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">35108582</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>LC</given-names></name><name><surname>Carneiro</surname><given-names>PP</given-names></name><name><surname>Fischer</surname><given-names>RG</given-names></name><name><surname>Tinoco</surname><given-names>EM</given-names></name></person-group><article-title>Presence of respiratory pathogens in the oral biofilm of patients with nosocomial pneumonia</article-title><source>Rev Bras Ter Intensiva</source><year>2007</year><volume>19</volume><fpage>428</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">25310158</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrouste-Orgeas</surname><given-names>M</given-names></name><name><surname>Chevret</surname><given-names>S</given-names></name><name><surname>Arlet</surname><given-names>G</given-names></name><name><surname>Marie</surname><given-names>O</given-names></name><name><surname>Rouveau</surname><given-names>M</given-names></name><name><surname>Popoff</surname><given-names>N</given-names></name></person-group><article-title>Oropharyngeal or gastric colonization and nosocomial pneumonia in adult intensive care unit patients. A prospective study based on genomic DNA analysis</article-title><source>Am J Respir Crit Care Med</source><year>1997</year><volume>156</volume><fpage>1647</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">9372689</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abele-Horn</surname><given-names>M</given-names></name><name><surname>Dauber</surname><given-names>A</given-names></name><name><surname>Bauernfeind</surname><given-names>A</given-names></name><name><surname>Russwurm</surname><given-names>W</given-names></name><name><surname>Seyfarth-Metzger</surname><given-names>I</given-names></name><name><surname>Gleich</surname><given-names>P</given-names></name></person-group><article-title>Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (SOD)</article-title><source>Intensive Care Med</source><year>1997</year><volume>23</volume><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">9069004</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scannapieco</surname><given-names>FA</given-names></name></person-group><article-title>Role of oral bacteria in respiratory infection</article-title><source>J Periodontol</source><year>1999</year><volume>70</volume><fpage>793</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">10440642</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>KK</given-names></name><name><surname>Baker</surname><given-names>D</given-names></name><name><surname>Quinn</surname><given-names>B</given-names></name></person-group><article-title>The epidemiology of nonventilator hospital-acquired pneumonia in the United States</article-title><source>Am J Infect Control</source><year>2018</year><volume>46</volume><fpage>322</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29050905</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wa&#x00142;aszek</surname><given-names>M</given-names></name><name><surname>R&#x000f3;zanska</surname><given-names>A</given-names></name><name><surname>Wa&#x00142;aszek</surname><given-names>MZ</given-names></name><name><surname>W&#x000f3;jkowska-Mach</surname><given-names>J</given-names></name></person-group><article-title>Epidemiology of ventilator-associated pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish intensive care units in the years 2013-2015</article-title><source>BMC Infect Dis</source><year>2018</year><volume>18</volume><fpage>308</fpage><pub-id pub-id-type="pmid">29976151</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarinfar</surname><given-names>N</given-names></name><name><surname>Ghaznavi-Rad</surname><given-names>E</given-names></name><name><surname>Mahmoodiyeh</surname><given-names>B</given-names></name><name><surname>Reyhani</surname><given-names>A</given-names></name></person-group><article-title>Comparison of three interventional approaches to prevent ventilator-associated pneumonia in intensive care units (ICUs): A clinical trial study</article-title><source>Qatar Med J</source><year>2021</year><volume>2021</volume><fpage>21</fpage><pub-id pub-id-type="pmid">34466393</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kes</surname><given-names>D</given-names></name><name><surname>Aydin Yildirim</surname><given-names>T</given-names></name><name><surname>Kuru</surname><given-names>C</given-names></name><name><surname>Pazarl&#x00131;oglu</surname><given-names>F</given-names></name><name><surname>Ciftci</surname><given-names>T</given-names></name><name><surname>Ozdemir</surname><given-names>M</given-names></name></person-group><article-title>Effect of 0.12% Chlorhexidine Use for Oral Care on Ventilator-Associated Respiratory Infections: A Randomized Controlled Trial</article-title><source>J Trauma Nurs</source><year>2021</year><volume>28</volume><fpage>228</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">34210941</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veitz-Keenan</surname><given-names>A</given-names></name><name><surname>Ferraiolo</surname><given-names>DM</given-names></name></person-group><article-title>Oral care with chlorhexidine seems effective for reducing the incidence of ventilator-associated pneumonia</article-title><source>Evid Based Dent</source><year>2017</year><volume>18</volume><fpage>113</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">29269816</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;z&#x000e7;aka</surname><given-names>&#x000d6;</given-names></name><name><surname>Ba&#x0015f;o&#x0011f;lu</surname><given-names>OK</given-names></name><name><surname>Buduneli</surname><given-names>N</given-names></name><name><surname>Ta&#x0015f;bakan</surname><given-names>MS</given-names></name><name><surname>Bacako&#x0011f;lu</surname><given-names>F</given-names></name><name><surname>Kinane</surname><given-names>DF</given-names></name></person-group><article-title>Chlorhexidine decreases the risk of ventilator-associated pneumonia in intensive care unit patients: a randomized clinical trial</article-title><source>J Periodontal Res</source><year>2012</year><volume>47</volume><fpage>584</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22376026</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakaya</surname><given-names>Z</given-names></name><name><surname>Duyu</surname><given-names>M</given-names></name><name><surname>Yersel</surname><given-names>MN</given-names></name></person-group><article-title>Oral mucosal mouthwash with chlorhexidine does not reduce the incidence of ventilator-associated pneumonia in critically ill children: A randomised controlled trial</article-title><source>Aust Crit Care</source><year>2022</year><volume>35</volume><fpage>336</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">34376358</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balshem</surname><given-names>H</given-names></name><name><surname>Helfand</surname><given-names>M</given-names></name><name><surname>Sch&#x000fc;nemann</surname><given-names>HJ</given-names></name><name><surname>Oxman</surname><given-names>AD</given-names></name><name><surname>Kunz</surname><given-names>R</given-names></name><name><surname>Brozek</surname><given-names>J</given-names></name></person-group><article-title>GRADE guidelines: 3. Rating the quality of evidence</article-title><source>J Clin Epidemiol</source><year>2011</year><volume>64</volume><fpage>401</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21208779</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munro</surname><given-names>CL</given-names></name><name><surname>Grap</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name><name><surname>McClish</surname><given-names>DK</given-names></name><name><surname>Sessler</surname><given-names>CN</given-names></name></person-group><article-title>Chlorhexidine, toothbrushing, and preventing ventilator-associated pneumonia in critically ill adults</article-title><source>Am J Crit Care</source><year>2009</year><volume>18</volume><fpage>428</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">19723863</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fourrier</surname><given-names>F</given-names></name><name><surname>Cau-Pottier</surname><given-names>E</given-names></name><name><surname>Boutigny</surname><given-names>H</given-names></name><name><surname>Roussel-Delvallez</surname><given-names>M</given-names></name><name><surname>Jourdain</surname><given-names>M</given-names></name><name><surname>Chopin</surname><given-names>C</given-names></name></person-group><article-title>Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients</article-title><source>Intensive Care Med</source><year>2000</year><volume>26</volume><fpage>1239</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">11089748</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segers</surname><given-names>P</given-names></name><name><surname>Speekenbrink</surname><given-names>RG</given-names></name><name><surname>Ubbink</surname><given-names>DT</given-names></name><name><surname>van Ogtrop</surname><given-names>ML</given-names></name><name><surname>de Mol</surname><given-names>BA</given-names></name></person-group><article-title>Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial</article-title><source>JAMA</source><year>2006;22</year><volume>296</volume><fpage>2460</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17119142</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e1;como</surname><given-names>AD</given-names></name><name><surname>Carmona</surname><given-names>F</given-names></name><name><surname>Matsuno</surname><given-names>AK</given-names></name><name><surname>Manso</surname><given-names>PH</given-names></name><name><surname>Carlotti</surname><given-names>AP</given-names></name></person-group><article-title>Effect of oral hygiene with 0.12% chlorhexidine gluconate on the incidence of nosocomial pneumonia in children undergoing cardiac surgery</article-title><source>Infect Control Hosp Epidemiol</source><year>2011</year><volume>32</volume><fpage>591</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21558772</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabov</surname><given-names>T</given-names></name><name><surname>Macan</surname><given-names>D</given-names></name><name><surname>Husedzinovi&#x00107;</surname><given-names>I</given-names></name><name><surname>Skrlin-Subi&#x00107;</surname><given-names>J</given-names></name><name><surname>Bosnjak</surname><given-names>D</given-names></name><name><surname>Sestan-Crnek</surname><given-names>S</given-names></name></person-group><article-title>The impact of oral health and 0.2% chlorhexidine oral gel on the prevalence of nosocomial infections in surgical intensive-care patients: a randomized placebo-controlled study</article-title><source>Wien Klin Wochenschr</source><year>2010</year><volume>122</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">20602280</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meidani</surname><given-names>M</given-names></name><name><surname>Khorvash</surname><given-names>F</given-names></name><name><surname>Abbasi</surname><given-names>S</given-names></name><name><surname>Cheshmavar</surname><given-names>M</given-names></name><name><surname>Tavakoli</surname><given-names>H</given-names></name></person-group><article-title>Oropharyngeal Irrigation to Prevent Ventilator-Associated-Pneumonia: Comparing Potassium Permangenate with Chlorhexidine</article-title><source>Int J Prev Med</source><year>2018</year><volume>9</volume><fpage>93</fpage><pub-id pub-id-type="pmid">30450176</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellissimo-Rodrigues</surname><given-names>F</given-names></name><name><surname>Bellissimo-Rodrigues</surname><given-names>WT</given-names></name><name><surname>Viana</surname><given-names>JM</given-names></name><name><surname>Teixeira</surname><given-names>GC</given-names></name><name><surname>Nicolini</surname><given-names>E</given-names></name><name><surname>Auxiliadora-Martins</surname><given-names>M</given-names></name></person-group><article-title>Effectiveness of oral rinse with chlorhexidine in preventing nosocomial respiratory tract infections among intensive care unit patients</article-title><source>Infect Control Hosp Epidemiol</source><year>2009</year><volume>30</volume><fpage>952</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19743899</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azimi</surname><given-names>M</given-names></name><name><surname>Jouybari</surname><given-names>L</given-names></name><name><surname>Moghadam</surname><given-names>S</given-names></name><name><surname>Ghaemi</surname><given-names>E</given-names></name><name><surname>Behnampoor</surname><given-names>N</given-names></name><name><surname>Sanagoo</surname><given-names>A</given-names></name></person-group><article-title>Antimicrobial effects of chlorhexidine, matrica drop mouthwash (chamomile extract), and normal saline on hospitalized patients with endotracheal tubes</article-title><source>Iran J Nurs Midwifery Res</source><year>2016</year><volume>21</volume><fpage>458</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">27904627</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusahara</surname><given-names>DM</given-names></name><name><surname>Peterlini</surname><given-names>MA</given-names></name><name><surname>Pedreira</surname><given-names>ML</given-names></name></person-group><article-title>Oral care with 0.12% chlorhexidine for the prevention of ventilator-associated pneumonia in critically ill children: randomised, controlled and double blind trial</article-title><source>Int J Nurs Stud</source><year>2012</year><volume>49</volume><fpage>1354</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">22771160</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klompas</surname><given-names>M</given-names></name><name><surname>Speck</surname><given-names>K</given-names></name><name><surname>Howell</surname><given-names>MD</given-names></name><name><surname>Greene</surname><given-names>LR</given-names></name><name><surname>Berenholtz</surname><given-names>SM</given-names></name></person-group><article-title>Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-analysis</article-title><source>JAMA Intern Med</source><year>2014</year><volume>174</volume><fpage>751</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24663255</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plantinga</surname><given-names>NL</given-names></name><name><surname>Wittekamp</surname><given-names>BHJ</given-names></name><name><surname>Leleu</surname><given-names>K</given-names></name><name><surname>Depuydt</surname><given-names>P</given-names></name><name><surname>Van den Abeele</surname><given-names>AM</given-names></name><name><surname>Brun-Buisson</surname><given-names>C</given-names></name></person-group><article-title>Oral mucosal adverse events with chlorhexidine 2% mouthwash in ICU</article-title><source>Intensive Care Med</source><year>2016</year><volume>42</volume><fpage>620</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">26850333</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berglund</surname><given-names>F</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>ME</given-names></name><name><surname>Martinsson</surname><given-names>A</given-names></name><name><surname>Ebmeyer</surname><given-names>S</given-names></name><name><surname>&#x000d6;sterlund</surname><given-names>T</given-names></name><name><surname>Johnning</surname><given-names>A</given-names></name></person-group><article-title>Comprehensive screening of genomic and metagenomic data reveals a large diversity of tetracycline resistance genes</article-title><source>Microb Genom</source><year>2020</year><volume>6</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">33125315</pub-id>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>CC</given-names></name><name><surname>Shen</surname><given-names>CF</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>WS</given-names></name></person-group><article-title>Recommendations and guidelines for the treatment of pneumonia in Taiwan</article-title><source>&#x0202f;J Microbiol Immunol Infect</source><year>&#x0202f;2019</year><volume>52</volume><fpage>172</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">30612923</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennesen</surname><given-names>P</given-names></name><name><surname>van der Ven</surname><given-names>A</given-names></name><name><surname>Vlasveld</surname><given-names>M</given-names></name><name><surname>Lokker</surname><given-names>L</given-names></name><name><surname>Ramsay</surname><given-names>G</given-names></name><name><surname>Kessels</surname><given-names>A</given-names></name></person-group><article-title>Inadequate salivary flow and poor oral mucosal status in intubated intensive care unit patients</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>781</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12626984</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Search strategies.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Database</th><th rowspan="1" colspan="1">Search strategy</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pubmed</td><td align="center" valign="middle" rowspan="1" colspan="1">Search&#x000a0;((((Oral hygiene[MeSH] OR oral hygiene[TIAB] OR Dental Hygiene[TIAB] OR Oral Care[TIAB] OR Dental Devices, Home Care[MeSH] OR dental floss[TIAB] OR toothpastes[MeSH] OR toothpaste[TIAB] OR dentifrices[MeSH] OR dentifrice*[TIAB] OR toothbrushing[MeSH] OR tooth brushing*[TIAB] OR chewing gum[MeSH] OR chewing gum*[TIAB] OR mouthwashes[MeSH] OR mouthwash*[TIAB] OR oral rinse*[TIAB])) AND (Inpatients[MeSH] OR Inpatient*[TIAB] OR Hospitalization[MESH] OR Hospitalization[TIAB] OR patient hospitalized[TIAB]OR critical care[MeSH] OR critical care[TIAB] OR Patient Care Bundles[MESH] OR care bundle*[TIAB])) AND (Cross Infection[MeSH] OR Cross Infection*[TIAB] OR Infection Healthcare associated[TIAB] OR Infections Healthcare associated[TIAB] OR Hospital Infection*[TIAB] OR Nosocomial Infection*[TIAB] OR Staphylococcus aureus[TIAB] OR Candida albicans[MESH] OR Candida albicans[TIAB] OR bacterial colonization[TIAB] OR Pneumonia[MESH] OR Pneumonia[TIAB]))</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Scopus</td><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000a0;TITLE-ABS-KEY&#x000a0;(&#x000a0;"Oral hygiene" OR "Dental Hygiene" OR "Oral Care" OR "Dental Devices, Home Care" OR "dental floss"&#x000a0;OR toothpaste OR toothpastes OR dentifrices OR dentifrice* OR toothbrushing OR "tooth brushing" OR "chewing gum" OR mouthwashes OR mouthwash OR "oral rinse"&#x000a0;)&#x000a0;) AND (&#x000a0;TITLE-ABS-KEY&#x000a0;(&#x000a0;inpatient* OR&#x000a0;inpatients&#x000a0;OR hospitalization OR "patient Hospitalized" OR "critical care" OR "Patient Care Bundles" OR "care bundle"&#x000a0;)&#x000a0;) AND (&#x000a0;TITLE-ABS-KEY&#x000a0;(&#x000a0;"Cross Infection" OR "Infection Healthcare associated" OR "Infections Healthcare associated" OR "Hospital Infection" OR "Nosocomial Infection" OR "Staphylococcus aureus" OR "Candida albicans" OR "bacterial colonization" OR pneumonia&#x000a0;)&#x000a0;)</td></tr><tr><td rowspan="47" colspan="1">Cochrane</td><td align="center" valign="middle" rowspan="1" colspan="1">ID; Search; Hits</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#1; MeSH descriptor: [Oral Hygiene] explode all trees; 2330</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#2; "oral hygiene" OR "Dental Hygiene" OR "Oral Care"; 6651</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#3; #1 OR #2; 7505</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#4; MeSH descriptor: [Dental Devices, Home Care] explode all trees; 380</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#5; "Dental floss"; 529</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#6; #4 OR #5; 846</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#7; MeSH descriptor: [Toothpastes] explode all trees; 868</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#8; "toothpaste"; 2248</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#9; #7 OR #8; 2497</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#10; MeSH descriptor: [Dentifrices] explode all trees; 1675</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#11; "dentifrice"; 1962</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#12; #10 OR #11; 2762</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#13; MeSH descriptor: [Toothbrushing] explode all trees; 1444</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#14; "tooth brushing"; 1090</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#15; #13 OR #14; 2293</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#16; MeSH descriptor: [Chewing Gum] explode all trees; 699</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#17; "chewing gum"; 1513</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#18; #16 OR #17; 1513</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#19; MeSH descriptor: [Mouthwashes] explode all trees; 1724</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#20; "mouthwash" OR "oral rinse" 2609</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#21; #19 OR #20; 3755</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#22; #3 OR #6 OR #9 OR #12 OR #15 OR #18 OR #21; 14399</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#23; MeSH descriptor: [Inpatients] explode all trees; 1111</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#24; "inpatient"; 15701</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#25; #23 OR #24; 16237</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#26; MeSH descriptor: [Hospitalization] explode all trees; 15459</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#27; "hospitalization" OR "patient hospitalized"; 50942</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#28; #26 OR #27; 58399</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#29; MeSH descriptor: [Critical Care] explode all trees; 2238</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#30; "Critical care"; 22461</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#31; #29 OR #30; 22804</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#32; MeSH descriptor: [Patient Care Bundles] explode all trees; 41</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#33; "patient care bundle"; 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#34; #32 OR #33; 41</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#35; #25 OR #28 OR #31 OR #34; 90924</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#36; MeSH descriptor: [Cross Infection] explode all trees; 1683</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#37; "cross infection" OR "infection healthcare associated" OR "hospital infection" OR "nosocomial infection" OR "staphylococcus aureus"; 6304</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#38; #36 OR #37; 6697</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#39; MeSH descriptor: [Candida albicans] explode all trees; 216</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#40; "Candida albicans" OR "bacterial colonization"; 2100</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#41; #39 OR #40; 2100</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#42; MeSH descriptor: [Pneumonia] explode all trees; 6517</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#43; "pneumonia"; 20285</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#44; #42 OR # 43; 22434</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#45; #38 OR #41 OR #44; 29210</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">#46; #22 AND #35 AND #45; 143</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">BVS</td><td align="center" valign="middle" rowspan="1" colspan="1">tw:((tw:(mh:"Oral hygiene" OR mh:"Higiene Bucal" OR tw:"Higiene Bucal" OR tw:"oral hygiene" OR tw:"Oral Care" OR tw:"cuidado oral" OR tw:"dental floss" OR tw:"Fio Dental" OR mh:toothpastes OR tw:toothpaste OR mh:"Cremes Dentais" OR tw:"Creme Dental" OR mh:dentifrices OR mh:dentifr&#x000ed;cios OR tw:dentifrice OR tw:dentifr&#x000ed;cio OR mh:toothbrushing OR mh:"escova&#x000e7;&#x000e3;o dent&#x000e1;ria" OR tw:toothbrushing OR tw:"escova&#x000e7;&#x000e3;o dent&#x000e1;ria" OR mh:mouthwashes OR mh:"Antiss&#x000e9;pticos Bucais" OR tw:"Antiss&#x000e9;pticos Bucais"))and (tw:((mh:inpatients OR mh:"Pacientes Internados" OR tw:inpatient OR tw:"Pacientes Internados" OR mh:hospitalization OR mh:hospitaliza&#x000e7;&#x000e3;o OR tw:hospitalization OR tw:hospitaliza&#x000e7;&#x000e3;o OR tw:"Patient hospitalized" OR tw:"paciente hospitalizado" OR mh:"critical care" OR mh:"cuidados cr&#x000ed;ticos" OR tw:"critical care" OR tw:"cuidados cr&#x000ed;ticos"))) AND (tw:((mh:"Cross Infection" OR mh:"Infec&#x000e7;&#x000e3;o Hospitalar" OR tw:"Cross Infection" OR tw:"Infec&#x000e7;&#x000e3;o Hospitalar" OR tw:"Staphylococcus aureus" OR tw:"Nosocomial Infection" OR tw:"Infec&#x000e7;&#x000e3;o Nosocomial" OR tw:"Candida albicans" OR mh:pneumonia OR tw:pneumonia ))))</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Web of Science</td><td align="center" valign="middle" rowspan="1" colspan="1">TS=(("Oral hygiene" OR "Dental Hygiene" OR "Oral Care" OR "Dental Devices, Home Care" OR "dental floss" OR toothpaste OR toothpastes OR dentifrices OR dentifrice* OR toothbrushing OR "tooth brushing" OR "chewing gum" OR mouthwashes OR mouthwash OR "oral rinse")) AND TS=(( inpatient* OR inpatients OR hospitalization OR "patient Hospitalized" OR "critical care" OR "Patient Care Bundles" OR "care bundle" )) AND TS=(( "Cross Infection" OR "Infection Healthcare associated" OR "Infections Healthcare associated" OR "Hospital Infection" OR "Nosocomial Infection" OR "Staphylococcus aureus" OR "Candida albicans" OR "bacterial colonization" OR pneumonia ))</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Open Gray</td><td align="center" valign="middle" rowspan="1" colspan="1">(tw:(mh:"Oral hygiene" OR mh:"Higiene Bucal" OR tw:"Higiene Bucal" OR tw:"oral hygiene" OR tw:"Oral Care" OR tw:"cuidado oral" OR tw:"dental floss" OR tw:"Fio Dental" OR mh:toothpastes OR tw:toothpaste OR mh:"Cremes Dentais" OR tw:"Creme Dental" OR mh:dentifrices OR mh:dentifr&#x000ed;cios OR tw:dentifrice OR tw:dentifr&#x000ed;cio OR mh:toothbrushing OR mh:"escova&#x000e7;&#x000e3;o dent&#x000e1;ria" OR tw:toothbrushing OR tw:"escova&#x000e7;&#x000e3;o dent&#x000e1;ria" OR mh:mouthwashes OR mh:"Antiss&#x000e9;pticos Bucais" OR tw:"Antiss&#x000e9;pticos Bucais")) AND (tw:(mh:inpatients OR mh:"Pacientes Internados" OR tw:inpatient OR tw:"Pacientes Internados" OR mh:hospitalization OR mh:hospitaliza&#x000e7;&#x000e3;o OR tw:hospitalization OR tw:hospitaliza&#x000e7;&#x000e3;o OR tw:"Patient hospitalized" OR tw:"paciente hospitalizado" OR mh:"critical care" OR mh:"cuidados cr&#x000ed;ticos" OR tw:"critical care" OR tw:"cuidados cr&#x000ed;ticos")) AND (tw:(mh:"Cross Infection" OR mh:"Infec&#x000e7;&#x000e3;o Hospitalar" OR tw:"Cross Infection" OR tw:"Infec&#x000e7;&#x000e3;o Hospitalar" OR tw:"Staphylococcus aureus" OR tw:"Nosocomial Infection" OR tw:"Infec&#x000e7;&#x000e3;o Nosocomial" OR tw:"Candida albicans" OR mh:pneumonia OR tw:pneumonia ))</td></tr></tbody></table><table-wrap-foot><fn><p>BVS: Biblioteca Virtual en Salud.
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Summary of characteristics of the included studies.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Authors/Year/Country</th><th rowspan="1" colspan="1">Blinding</th><th rowspan="1" colspan="1">Sampling method</th><th rowspan="1" colspan="1">Sample source</th><th rowspan="1" colspan="1">Age</th><th rowspan="1" colspan="1">Intervention</th><th rowspan="1" colspan="1">Control</th><th rowspan="1" colspan="1">Presentation form</th><th rowspan="1" colspan="1">Time</th><th rowspan="1" colspan="1">CHX concentration</th><th rowspan="1" colspan="1">Way of use</th><th rowspan="1" colspan="1">Professional</th><th rowspan="1" colspan="1">Frequency</th><th rowspan="1" colspan="1">Days in the ICU</th><th rowspan="1" colspan="1">Type of infection</th><th rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Karakaya, <italic>et al.</italic> / Turkey
(15)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">Pediatric ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">1 month -
18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (70) CHX CG: (68) Nacl 0,9%</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(5 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">Swab</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">6x</td><td align="center" valign="middle" rowspan="1" colspan="1">GI: 12 (7-21)
GC: 10 (5-17)
P = 0.309</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">The use of 0.12% CHX did not reduce VAP frequency among critically ill children.
GI: 21/70 &#x000d7; GC:22/68</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dale, <italic>et al.</italic>
(2021) / Canada
(3)</td><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">CG: (947) CHX IG: (987) Tooth brushing</td><td align="center" valign="middle" rowspan="1" colspan="1">Tooth
brushing</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">No benefit was observed for
de-adoption of CHX.
IG:24/947 &#x000d7; IC:48/987</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alja'afreh, <italic>et al.</italic> (2019) / Jordan
(2)
</td><td align="center" valign="middle" rowspan="1" colspan="1">Blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (102) Tooth brushing e CHX CG: (116) Tooth brushing</td><td align="center" valign="middle" rowspan="1" colspan="1">Tooth
brushing</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05%</td><td align="center" valign="middle" rowspan="1" colspan="1">Swab</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">GC: 7.1 (2.3)
GI: 5.4 (1.8)
P=.041</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">The VAP incidence was significantly lower in the intervention group.
CG:41/116 &#x000d7; IG: 22/102
CG: 35.3 &#x000d7; IG: 21.6 p=.018</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Meidani, <italic>et al.</italic> (2018)
/ Dubai
(22)</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">G1: (50) CHX G2: (50) Potassium permanganateG3: (50) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(10 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">17.5 &#x000b1;30.3
10.9 &#x000b1; 19.3
P &#x0003c;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">The use of mouthwashes, especially CHX, decreased the incidence of VAP.
G1: 6/50 (12%), G2: 7/50 (14%), G3: 15/50 (30%); p = 0.041.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Azimi, <italic>et al.</italic>
(2016) / Iran
(24)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Raffle
through a box</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 15 years</td><td align="center" valign="middle" rowspan="1" colspan="1">G1: (13) CHX GC (13) Matrica G3: (13) Saline solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Matrica / saline solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(10mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">Gloved hands</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurse</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">CHX was more effective on the bacterial colonization in comparison with Matrica and normal saline.
IG (CHX): 3/13 GCM: 8/13
GCS (control):10/13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kusahara <italic>et al.</italic>
(2012) / Brazil
(30)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">Pediatric ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">GI:12 &#x000b1; 49.75
GC: 4&#x000b1; 58.8
P = 0.023</td><td align="center" valign="middle" rowspan="1" colspan="1">GI: (46) Tooth brushing + CHXCG: (50) Tooth brushing + placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
dental gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Gel</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">Swab</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">2&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 15.8 &#x000b1; 23.6
CG: 10.8 &#x000b1; 8.32
P = 0.777</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">No significant differences were observed in VAP incidence with the use of CHX 0,12%.
GI:15/46 GC:16/50
IG: 32.6% &#x000d7; CG: 32.0 p=0.949</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x000d6;z&#x000e7;aka, <italic>et al.</italic>
(2012) / Turkey
(14)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Subject identification numbers</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (29) CHX CG: (32) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Saline
solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(30 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">Swab</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 12.2 &#x000b1; 11.3 CG: 15.4 &#x000b1; 3.5.P = 0.279</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP was significantly higher in the control group.
GI:12/29 GC:22/32
CG: 68.8% &#x000d7; IG:41.4%; p=0.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">J&#x000e1;como, <italic>et al.</italic> (2011) / Brazil
(20)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">Pediatric ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">Median
12.2 vs 10.8 months
(p = 0.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (87) CHX CG: (73) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c; 1 year: gauze &#x0003e; 6 year: mouthwash</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">2&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">Median
IG:3 &#x000d7; CG:4 P=0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP / nosocomial</td><td align="center" valign="middle" rowspan="1" colspan="1">Oral hygiene with CHX 0,12% not reduce nocomial infection and VAP in children undergoing cardiac surgery.
Nosocomial infections:
GI:26/87 GC:18/73
IG 29.8 % &#x000d7; CG 24.6%; P=0.46
VAP incidence:
18.3 % &#x000d7; 15%; p= 0.57</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cabov, <italic>et al.</italic> (2010) / Croatia
(21)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (30) CHX CG: (30) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
dental gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Remained in the mouth</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">Gloved hands</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 5.1 &#x000b1; 1.6
CG: 6.8 &#x000b1; 3.5
P = 0.019</td><td align="center" valign="middle" rowspan="1" colspan="1">Nosocomial</td><td align="center" valign="middle" rowspan="1" colspan="1">Oral hygiene with CHX 0,2% decreased oral colonization, the incidence of nosocomial infection and length of ICU.
IG:2/30 (6.7%) CG:8/30 (26.7%)
p=0.0418</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Munro, <italic>et al.</italic>
(2009) / United Stated
(17)</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">Permuted block</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">G1: (57) CHX G2: (63) Tooth brushing G3: (65) Tooth brushing + CHXG4: (64) Control</td><td align="center" valign="middle" rowspan="1" colspan="1">Tooth
brushing</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(5mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">Swab</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">2&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">CG: 10.7
IG: 10.8</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP</td><td align="center" valign="middle" rowspan="1" colspan="1">CHX but not toothbrushing reduces the incidence of early VAP.
VAP incidence:
IG: 24/57 CG:31/6z</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bellissimo-Rodrigues, <italic>et al.</italic>
(2009) / Brazil
(23)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Raffle
through a box</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 15 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (98) CHX CG: (96) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(15mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 %</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouthwash</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 9.7 CG: 10.4
P=0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP / nosocomial</td><td align="center" valign="middle" rowspan="1" colspan="1">VAP incidence
IG: 22.6 CG: 22.3; p=0.95
Nosocomial infection
GI:21/98 GC:25/96
CG:25 &#x000d7; IG: 22.2; p=1.00 (0.63 -1.60)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Segers, <italic>et al.</italic> (2006) / Amsterdam
(19)</td><td align="center" valign="middle" rowspan="1" colspan="1">Double-blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">Hospitalized</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (485) CHX CG: (469) Placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
solution</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution
(10 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 %</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouthwash</td><td align="center" valign="middle" rowspan="1" colspan="1">Patient/ Nurse</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 1.4
CG: 2.6
P=0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">Nosocomial</td><td align="center" valign="middle" rowspan="1" colspan="1">The incidence of nosocomial infection appears to be lower with CHX.
IG: 116/485 (19.8%)
CG: 164/469 (26.2%) p=0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fourrier, <italic>et al.</italic> (2000) / France
(18)</td><td align="center" valign="middle" rowspan="1" colspan="1">Blind</td><td align="center" valign="middle" rowspan="1" colspan="1">Computerized list</td><td align="center" valign="middle" rowspan="1" colspan="1">ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265; 18 years</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: (30) CHX CG: (30) Tooth brushing + placebo</td><td align="center" valign="middle" rowspan="1" colspan="1">Placebo
dental gel</td><td align="center" valign="middle" rowspan="1" colspan="1">Gel</td><td align="center" valign="middle" rowspan="1" colspan="1">NR</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">Gloved hands</td><td align="center" valign="middle" rowspan="1" colspan="1">Nurses</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x000d7;</td><td align="center" valign="middle" rowspan="1" colspan="1">IG: 18%
CG: 33%
p= &#x0003e;0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">Nosocomial</td><td align="center" valign="middle" rowspan="1" colspan="1">No significant differences were observed.
IG:8/30 CG: 17/30
IG: 26.6% &#x000d7; CG: 56.6% p=0.018</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Certainty of evidence.&#x000a0;</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="2" colspan="1">
</th><th colspan="6" rowspan="1">Certainty assessment</th><th colspan="2" rowspan="1">N&#x000ba; of patients</th><th rowspan="2" colspan="1">Certainty</th></tr><tr><th rowspan="1" colspan="1">N&#x000ba; of studies
Study design</th><th rowspan="1" colspan="1">Risk of bias</th><th rowspan="1" colspan="1">Inconsistency</th><th rowspan="1" colspan="1">Indirectness</th><th rowspan="1" colspan="1">Imprecision</th><th rowspan="1" colspan="1">Other considerations</th><th rowspan="1" colspan="1">Chlorexidine</th><th rowspan="1" colspan="1">Control</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nosocomial infection</td><td align="center" valign="middle" rowspan="1" colspan="1">13
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">none</td><td align="center" valign="middle" rowspan="1" colspan="1">300/2044 (14.7%)</td><td align="center" valign="middle" rowspan="1" colspan="1">437/2077 (21 %)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x02a01;&#x000a0;MODERATE</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VAP infection</td><td align="center" valign="middle" rowspan="1" colspan="1">10
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">none</td><td align="center" valign="middle" rowspan="1" colspan="1">159/1499 (10.6%)</td><td align="center" valign="middle" rowspan="1" colspan="1">233/1548 (15.1%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x02a01;&#x02a01;&#x000a0;MODERATE</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nosocomial infection not PAV</td><td align="center" valign="middle" rowspan="1" colspan="1">5
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">none</td><td align="center" valign="middle" rowspan="1" colspan="1">173/730 (10%)</td><td align="center" valign="middle" rowspan="1" colspan="1">232/698 (33.2%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x02a01;LOW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">S. aureus</td><td align="center" valign="middle" rowspan="1" colspan="1">5
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">very serious <sup>b,d</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">strong association</td><td align="center" valign="middle" rowspan="1" colspan="1">4/161 (2.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">12/186 (6.5%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x02a01;LOW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Days hospitalized</td><td align="center" valign="middle" rowspan="1" colspan="1">3
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>f</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>e</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">none</td><td align="center" valign="middle" rowspan="1" colspan="1">678</td><td align="center" valign="middle" rowspan="1" colspan="1">592</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;VERY LOW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Days admitted in ICU</td><td align="center" valign="middle" rowspan="1" colspan="1">7
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>f</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>e</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">none</td><td align="center" valign="middle" rowspan="1" colspan="1">840</td><td align="center" valign="middle" rowspan="1" colspan="1">843</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x000a0;VERY LOW</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of mechanical ventilation</td><td align="center" valign="middle" rowspan="1" colspan="1">4
randomized trials</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">very serious <sup>f,h</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">not serious</td><td align="center" valign="middle" rowspan="1" colspan="1">serious <sup>e</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">strong association</td><td align="center" valign="middle" rowspan="1" colspan="1">275</td><td align="center" valign="middle" rowspan="1" colspan="1">294</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02a01;&#x000a0;VERY LOW</td></tr></tbody></table><table-wrap-foot><fn><p>CI: Confidence interval; RR: Risk ratio; MD: Mean difference; a. All included studies presented risk of bias; b. Upper or lower limit of confidence interval is greater than 25% of RR; c. Exclusion of studies with some risk of bias change the significance; d. Number of events is lower than 300; e. Upper or lower confidence limit crosses the effect size of 0.5 in either direction; f. Significant heterogenenity; h. Wide variation in the effect estimates across studies.
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Subgroup analysis results.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th colspan="2" rowspan="1">Parameter</th><th rowspan="1" colspan="1">Number of studies</th><th rowspan="1" colspan="1">I<sup>2</sup></th><th rowspan="1" colspan="1">Risk ratio</th><th rowspan="1" colspan="1">Confidence interval</th><th rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" colspan="1">Antibiotic prophylaxis</td><td align="center" valign="middle" rowspan="1" colspan="1">With prophylaxis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">3%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.59, 0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Without prophylaxis</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">45%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.32, 0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="2" align="center" valign="middle" colspan="1">Previous infection (PI)</td><td align="center" valign="middle" rowspan="1" colspan="1">Included patients with PI</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63, 1.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Not included patients with PI</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">29%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41, 0.93</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">CHX concentration</td><td align="center" valign="middle" rowspan="1" colspan="1">CHX 0.05%</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.39, 0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CHX 0.12%</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">31%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66, 0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CHX 2%</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35, 0.68</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td rowspan="3" align="center" valign="middle" colspan="1">CHX administration</td><td align="center" valign="middle" rowspan="1" colspan="1">Twice daily</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75, 1.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Three times daily</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">23%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34, 0.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Four times daily or more</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57, 0.78</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></table-wrap></floats-group></article>